Imatinib Withdrawn Phase 2 Trials for Metastatic Solid Tumors Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00159016Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.